Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Induction chemotherapy followed by neoadjuvant chemoradiotherapy and surgery in locally advanced rectal cancer
IRCT20200420047139N1Phase 2Completed
- Sponsor
- Shahid Beheshti University of Medical Sciences
- Start
- May 2018
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of capecitabine and oxaliplatin in rectal cancer, sponsored by Shahid Beheshti University of Medical Sciences. Primary endpoints: Pathologic complete response, R0 resection rate and 4 more. Started May 2018; status: completed.
02
Drugs
capecitabineoxaliplatin
03
Conditions
rectal cancer
Beyond the preview
Go deeper on IRCT20200420047139N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20200420047139N1.